Introduction
Multiple myeloma (MM) remains an incurable disease despite conventional chemotherapy as well as high-dose therapy with autologous stem cell transplantation. It is estimated that there will be 15 270 new cases of MM diagnosed in the United States and 11 070 deaths attributed to this disease in 2004 alone, 1 and development of targeted therapies based on better understanding of the disease biology is needed. The bone marrow (BM) microenvironment plays a major role in MM and new treatments should be able to target the microenvironment as well as tumor, to be effective. Thalidomide was introduced in myeloma due to its antiangiogenic properties, and multiple clinical trials have since confirmed its efficacy in patients with relapsed, refractory MM, as well as newly diagnosed disease. 2, 3 The side effect profile and the potential for teratogenicity from thalidomide have provided the impetus to identify analogs that retain its anti-MM activity, without the teratogenic effects. Identification of the active thalidomide metabolites responsible for the individual effects can potentially permit synthesis of more targeted compounds. One of the products of cytochrome P450 2C19 isozyme biotransformation of thalidomide, 5 0 -OHthalidomide, retains significant antiangiogenic activity. [4] [5] [6] Based on the structure of this metabolite, several N-substituted and tetraflourinated thalidomide analogs have been synthesized, which have antiangiogenic activity in the rat aortic ring assay. 7 Some of these drugs have activity against prostate cancer in vitro, and are moving into early phase clinical trials. We demonstrate that CPS11 (N-substituted thalidomide) and CPS49 (tetraflourinated thalidomide) can overcome conventional drug resistance in the BM milieu, providing the framework for clinical evaluation to improve patient outcome in MM.
Methods

MM-derived cell lines
Dexamethasone-sensitive (MM.1S) and dexamethasone-resistant (MM.1R) human MM cell lines (Dr Steven Rosen, Northwestern University, Chicago, IL, USA); doxorubicin-resistant (Dox 40), mitoxantrone-resistant (MR20), and melphalanresistant (LR5) RPMI-8226 human MM cells and sensitive RPMI-8226 cell lines (Dr William Dalton, Moffitt Cancer Center, Tampa, FL, USA); OPM2 cell line (Dr Lief Bergsagel, Cornell University, NY, USA); SB645 (myeloma cell line with constitutively active IL-6 promoter; Dr Kishimoto, Osaka University, Japan); DHL4 cell line (Dr Margaret Shipp, Dana-Farber Cancer Institute, Boston, MA, USA); NCI-H929, U266, and L363 cell lines (ATCC, Rockville, MD, USA) were all cultured in RPMI-1640 media (Sigma Chemical, St Louis, MO, USA) that contained 10% fetal bovine serum, 2 mmol/l L-glutamine (GIBCO, Grand Island, NY, USA), 100 U/ml penicillin, and 100 mg/ml streptomycin.
CPS49 and CPS11
Thalidomide analogs CPS11 and CPS49 were kindly provided by Dr William D Figg (National Cancer Institute, Bethesda, MD, USA). The drugs were dissolved in DMSO (Sigma Chemical, St Louis, MO, USA) at a concentration of 200 mmol/l (200 mM) and stored at À201C until use. Drugs were diluted in culture medium (0.01-100 mM) to a final DMSO concentration of o0.1% immediately before use, and diluted drugs were used within 4 h.
BM stromal cells (BMSCs) and coculture
Freshly obtained BM aspirates were subjected to Ficoll-Paque gradient separation to isolate mononuclear cells (MNCs). These cells were placed in 25 mm 2 culture flasks in RPMI-1640 media containing 20% fetal bovine serum, 2 mmol/l L-glutamine, 100 U/ml penicillin, and 100 mg/ml streptomycin. Once the BMSC were confluent, they were trypsinized and passaged as needed. The cytotoxicity of the drugs was confirmed by colorimetric assay using 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrasodium bromide (MTT; Chemicon International Inc., Temecula, CA, USA). Cells from 48-h cultures were pulsed with 5 mg/ml MTT (10 ml/well); 96-well plates were incubated at 371C for 4 h, followed by 100 ml isopropanol containing 0.04 N HCl. Absorbance at a wavelength of 570 nm (with correction at 630 nm) were measured on a spectrophotometer (Molecular Devices Corp., Sunnyvale, CA, USA). All experiments were performed in triplicate.
Detection of apoptosis in myeloma cell lines and patient myeloma cells
Apoptotic cells were detected using Annexin V-PE apoptosis detection kit I (BD Pharmingen), according to the manufacturer's instructions. Briefly, MM cells (1 Â 10 6 ) were cultured in media alone, or with varying concentrations of CPS11 or CPS49, and harvested every 6 h for 24 h. Cells were washed twice with icecold PBS and resuspended (1 Â 10 6 cells/ml) in binding buffer (10 mmol/l HEPES, pH 7.4, 140 mmol/l NaCl, 2.5 mmol/l CaCl 2 ). MM cells (1 Â 10 5 ) were incubated with Annexin V-PE (5 ml) and 7-AAD (5 mg/ml) for 15 min at room temperature. The cells were analyzed using RXP Cytomics software on an Epics flow cytometer (Coulter Immunology, Hialeah, FL, USA).
For evaluation of patient MM cells, BM aspirates were subjected to Ficoll-Paque gradient and the separated MNC were suspended in RPMI-1640 media containing 20% fetal bovine serum, 2 mmol/l L-glutamine, 100 U/ml penicillin, and 100 mg/ml streptomycin, placed in 24-well plates, and CPS11 or CPS49 added. Patient cells were cultured for 48 h, harvested, and washed twice with PBS, and double stained with FITCconjugated CD38 monoclonal antibody and PE-conjugated Apo 2.7 antibody. The percentage of CD38 bright Apo 2.7-positive apoptotic MM cells was calculated by flow cytometry. BM aspirates were obtained under an existing IRB-approved protocol with informed consent.
Western blotting
MM cells were cultured with 50 mmol/l of CPS11 or CPS49; harvested; washed; and lysed using lysis buffer (50 mmol/l HEPES (pH 7.4), 150 mmol/l NaCl, 1% Triton X-100, 30 mmol/l sodium pyrophosphate, 5 mmol/l EDTA, 2 mmol/l Na 3 VO 4 , 5 mmol/l NaF, 1 mmol/l phenylmethyl sulfonyl fluoride, 5 mg/ ml leupeptin, and 5 mg/ml aprotinin). Cell lysates were subjected to SDS-PAGE, transferred to nitrocellulose membrane, and immunoblotted with antibodies against cleaved PARP and cleaved caspase-8 (Cell Signaling Technology, MA, USA). To characterize growth signaling, immunoblotting was carried out with anti-phospho-specific p38-MAPK Ab, antiphospho-extracellular signal-regulated kinase (ERK)1/2, antiphospho-MEK1/2, antiphospho-signal transducers and activators of transcription 3 (STAT3), and antiphospho-Akt (Cell Signaling Technology, MA, USA). The effect of both drugs on various antiapoptotic proteins was studied in a similar manner using antibodies against bcl2, Bcl-xL, Mcl1, and XIAP (Cell Signaling Technology, MA, USA). Antigen-antibody complexes were detected using enhanced chemiluminescence (Amersham, Arlington Heights, IL, USA). Blots were stripped and reprobed with anti-actin Ab (Santa Cruz Biotech) or anti-a-tubulin to ensure equivalent protein loading.
Angiogenesis assay
The effect of CPS11 and CPS49 on angiogenesis was determined using a matrigel-based in vitro angiogenesis kit (ECM625; Chemicon International, Temecula CA, USA). Briefly, The ECMatrixt solution was mixed with provided diluent, and plated (50 ml/well) in a 96-well plate, followed by 2 h incubation to allow the matrix to solidify. HUVECs were harvested, resuspended in EGM2 media (Cambrex, NJ, USA) with or without varying concentrations of CPS49 and CPS11, and added to a plate containing the matrigel (10 000 cells/well). The plate was incubated at 371C and then inspected for tubule formation starting at 8 h. The wells were photographed after 12 h incubation ( Â 100 magnification) using an inverted phase microscope.
ELISA
The effects of CPS49 and CPS11 on cytokine secretion by human BMSCs cocultured with MM cells were studied using ELISA for IL-6, VEGF, and IGF-1. BMSCs were cultured in 96-well plates with varying concentrations of CPS11 or CPS49 with or without MM1.S cells. After 24-h incubation, the supernatants were harvested and stored at À701C until measurement. Cytokines were measured using Duoset s ELISA Development Kits (R&D Systems, Minneapolis, MN, USA). All measurements were carried out in duplicate.
Results
Effect of CPS11 and CPS49 on DNA synthesis by MM cell lines CPS49, and to a lesser extent CPS11, inhibited proliferation of MM.1S (Figure 1a) , OPM2, RPMI-8226, L363, and SB645 cells (IC 50 values are shown in Figure 1d ) in a dose-dependent manner. In all, 55% inhibition was noted at 5 mmol/l CPS49 and 20-50 mmol/l CPS11. Treatment resulted in dose-dependent 
CPS11 and CPS49 induce apoptosis of MM cell lines and patient myeloma cells
In order to further delineate the mechanism of cytotoxicity, MM1.S cells incubated for 24-48 h with media alone, CPS11 (50 mmol/l), or CPS49 (50 mmol/l) were analyzed for apoptosis using flow cytometry. As shown in Figure 3a , a time-dependent increase in apoptotic and necrotic tumor cells was induced by CPS49. A similar, but less pronounced effect was seen after CPS11 treatment of MM1.S cells (data not shown).
Freshly isolated MNC from BM of patients with MM were treated with CPS11 or CPS49 for 48 h. A 40% increase in the apoptotic CD38-positive cells was observed following treatment with CPS49 at high (20 and 50 mmol/l) doses. A less prominent effect was noted after therapy with CPS11. Three different patient samples were analyzed with similar results. A representative result is shown in Figure 3b . To determine whether the effect of CPS11 and CPS49 on patient myeloma cells were independent of its effect on normal peripheral blood mononuclear cells (PBMCs), Ficoll-Paque separated PBMC from two different donors were treated with varying doses (0.01-100 mmol/l) of CPS49 or CPS11. No cytotoxic effects were seen with CPS11 at doses up to 100 mmol/l, and with CPS49 at doses up to 50 mmol/l. 
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To further understand the apoptotic signaling induced by these drugs in MM cell lines, MM1.S cells were incubated with media alone, CPS11 (50 mmol/l), or CPS49 (50 mmol/l) for 24-48 h. A time-dependent increase in the PARP and caspase-8 cleavage was observed after treatment with CPS11 or CPS49 (Figure 3d) . No cleavage of caspase-9 was noted (data not shown). The addition of the pancaspase inhibitor ZVAD-fmk partially inhibited cytotoxicity of CPS11 (Figure 3e ), but not of CPS49 (data not shown).
The effect of CPS11 and CPS49 on intracellular signaling pathways known to mediate MM cell growth, survival, and drug resistance was next studied (Figure 4a ). Both drugs inhibited the baseline phosphorylation of STAT3, CPS49 to a greater extent than CPS11. Both drugs also decreased phosphorylation of Akt, following an initial increase in the pAkt at 1-2 h. Both the drugs induced MAPK pathway as evidenced by increased phosphorylation of ERK1/2 as well as p38MAPK. Functional significance of this upregulation was examined by the addition of the MEK inhibitor U0126, which enhanced the cytotoxicity of both the drugs against MM1.S cells (Figure 4b ).
We also studied the effect of the drugs on the expression of antiapoptotic proteins Bcl-xL, Mcl1, and XIAP using MM1.S cells. The downregulation of Mcl1 was noted with both CPS11 and CPS49, where as an effect on XIAP was noted only with CPS49 and no effect was seen on BCL-xL with either of the drugs (Figure 4c ).
CPS11 and CPS49 have antiangiogenic properties
CPS49, and to a lesser extent CPS11, demonstrated a dosedependent inhibition of tubule formation by HUVECs. The addition of CPS49 (10 mmol/l) significantly inhibited tubule or vessel formation, but CPS11 had such an effect only at the highest (100 mmol/l) dose (Figure 5a ). More importantly, the effect on tube formation was independent of any effect on cell viability as demonstrated by the MTT assays. CPS11 had no direct effect on the HUVEC viability, and CPS49 was cytotoxic only at the highest dose (50-100 mmol/l) (Figure 5b ).
CPS11 and CPS49 have direct effect on BMSCs
When BMSCs were pretreated with CPS11 or CPS49 for 24 h prior to coculture with MM1.S cells, the normal proliferative effect of BMSCs on myeloma cells was inhibited (Figure 6a ). This effect was more prominent for CPS49. Additionally, CPS49 inhibited the normal increase in the secretion of IL-6, VEGF, and IGF by BMSCs induced by binding of MM cells (Figure 6b-d) . This inhibitory effect was minimal for CPS11 (data not shown). 
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Discussion
Improved understanding of the disease biology has resulted in several therapeutic advances in MM, including thalidomide and IMiDs as well as the proteasome inhibitor PS341 (Velcade s ), which was recently approved by FDA for treatment of relapsed, refractory myeloma. Multiple mechanisms have been proposed for the anti-MM activity of thalidomide and its analogs as follows: modulation of cytokines essential for MM growth and survival, antiangiogenesis, 9,10 immunomodulation, 11 and blockade of intracellular signaling pathways mediating MM cell growth and survival.
8 CPS11 and CPS49 are two compounds that have been derived from a thalidomide metabolite with antiangiogenic activity.
In this study, we demonstrate the in vitro anti-MM activity of the N-substituted thalidomide analog CPS11 and the tetraflourinated analog CPS49. Both drugs exhibit excellent activity against a wide array of MM cell lines, CPS49 being more potent compared to CPS11. There also appear to be differences between the drugs in terms of activity spectrum, as CPS49 but not CPS11 demonstrates cytotoxicity against U266 and NCI-H929 MM cell lines. This lack of activity against U266 is similar to that previously observed with thalidomide and ImiDs. 8 Both drugs also inhibit proliferation in MM cell lines resistant to dexamethasone, anthracyclines, or melphalan, demonstrating lack of crossresistance and indicating nonoverlapping mechanisms of action. Additionally, they inhibited proliferation of DHL4 cells, a lymphoid cell line (DHL4) intrinsically resistant to the proteasome inhibitor PS341, 12 suggesting that they can overcome mechanisms of proteasome inhibitor resistance. The antitumor activity is similar to that seen with prostate cancer cell lines, where treatment with CPS11 and CPS49 has led to regression of subcutaneous implanted tumors in SCID mice. 13 Although CPS11 was more potent than CPS49 against prostate cancer, our findings suggest that CPS49 is more potent in the setting of MM.
Given the important role of BM microenvironment in MM in promoting tumor cell growth and drug resistance, it is of particular importance that these drugs were able to overcome the protective effects against conventional therapy conferred by coculture of MM cells with BMSCs as well as by high concentrations of IL-6, IGF, and VEGF, confirming their ability to target tumor cells in the BM microenvironment. When evaluated against MM cells freshly isolated from patient with myeloma, both drugs induced dose-dependent apoptosis. Lack of cytotoxicity against normal PBMC at doses effective against We also studied the effects of CPS11 and CPS49 on signaling cascades mediating MM cell growth and survival. Caspasemediated apoptosis triggered by CPS11 and CPS49 was seen in the MM cells, which was only partially blocked by pancaspase inhibitor ZVAD-fmk in case of CPS11. No effect was seen with CPS49, suggesting alternate mechanisms of cell death as well. Similar changes have been shown with MM cell lines treated with ImiDs. 14 We and others have shown that MM cell growth and survival is mediated via ERK, 15 Akt, 16 and JAK/STAT3 signaling. 17 Here, we showed drug-induced decrease in phosphorylation STAT3 and Akt consistent with the downregulation of survival signaling, but increased phosphorylation of ERK and p38MAPK. The upregulation of ERK cascade with these drugs may be a protective response, since addition of an MEK inhibitor enhances cytotoxicity. These preclinical findings also provide the rationale for combining CPS11 and CPS49 with inhibitors of the MAPK pathway currently under development. Finally, we also show downregulation of antiapoptotic proteins Mcl1 and XIAP, especially triggered by CPS49, as another potential mechanism for the anti-MM activity. However, no change was noted in the bcl-xL expression. The downregulation of bcl2 has been previously reported following thalidomide treatment, but was not observed with these drugs.
Increased BM angiogenesis appears to be important in MM pathogenesis and progression. 18, 19 The ability of these new compounds to inhibit angiogenesis, as demonstrated by the CPS11 and CPS49 have antiangiogenic properties. CPS11 (upper panels) and CPS49 (lower panels) induce dose-dependent inhibition of tube formation by HUVECs plated on matrigel (a). At the highest doses of CPS11 or CPS49, there is virtually no tube formation. The photomicrographs were obtained using an Olympus D-270 digital camera at Â 100 magnification using an inverted phase microscope. When HUVECs were treated, no toxicity was seen with CPS11 at doses up to 100 mmol/l (MTT assay). CPS49, however, resulted in toxicity at highest doses (50-100 mmol/l).
matrigel-based assay, may also contribute to the anti-MM effect. Previous studies have also shown that these analogs inhibit angiogenesis in rat aortic ring and human saphenous vein assays. 7 The tetraflourinated analog CPS49 was more potent in inhibiting endothelial cell function, consistent with previous observations. 7 CPS49 can decrease intratumoral vascularity in xenograft models of prostate cancer via inhibition of PDGF. 13 Ongoing studies in animal models of MM will evaluate whether antiangiogenesis correlates with MM responses. Finally, immunomodulation contributes to the anti-MM activity of thalidomide and many of its analogs, 20 and ongoing studies are evaluating the effects of CPS11 and CPS49 on NK and T cells.
In summary, we demonstrate that the N-substituted thalidomide analog CPS11 and the tetraflourinated analog CPS49 have significant anti-MM activity in vitro. This activity, which overcomes the protective effect of BMSCs and cytokines, is associated with and possibly mediated through downregulation of antiapoptotic proteins and blockade of signaling cascades mediating MM growth and survival. Additionally, we demonstrate the antiangiogenic properties of these novel agents, as well as their direct effect on the BM stroma. These data provide the preclinical rationale for evaluation in clinical trials to improve outcome of patients with MM. Novel thalidomide analogs in myeloma S Kumar et al
